Global Adrenocorticotropic Hormone ACTH
Market Report
2025
The global Adrenocorticotropic Hormone Market size will be USD 1524.8 million in 2025. Increasing prevalence of endocrine and autoimmune disorders and growing adoption of ACTH for diagnostic and therapeutic applications is expected to boost sales to USD 2119.1 million by 2033, with a Compound Annual Growth Rate (CAGR) of 4.20% from 2025 to 2033.
The base year for the calculation is 2024. The historical will be 2021 to 2024. The year 2025 will be estimated one while the forecasted data will be from year 2025 to 2033. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Adrenocorticotropic Hormone ACTH Market Report 2025.
According to Cognitive Market Research, the global Adrenocorticotropic Hormone Market size will be USD 1524.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 4.20% from 2025 to 2033.
2021 | 2025 | 2033 | CAGR | |
---|---|---|---|---|
Global Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 1524.8 Million | $ 2119.1 Million | 4.2% |
North America Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 564.18 Million | $ 699.3 Million | 2.7% |
United States Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 445.13 Million | 121212 | 2.5% |
Canada Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 67.7 Million | 121212 | 3.5% |
Mexico Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 51.34 Million | 121212 | 3.2% |
Europe Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 442.19 Million | $ 572.2 Million | 3.3% |
United Kingdom Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 74.29 Million | 121212 | 4.1% |
France Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 40.68 Million | 121212 | 2.5% |
Germany Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 87.55 Million | 121212 | 3.5% |
Italy Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 38.03 Million | 121212 | 2.7% |
Russia Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 68.54 Million | 121212 | 2.3% |
Spain Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 36.26 Million | 121212 | 2.4% |
Sweden Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 13.71 Million | 121212 | 3.4% |
Denmark Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 9.29 Million | 121212 | 3.1% |
Switzerland Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 6.63 Million | 121212 | 2.9% |
Luxembourg Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 5.31 Million | 121212 | 3.6% |
Rest of Europe Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 61.91 Million | 121212 | 2% |
Asia Pacific Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 365.95 Million | $ 622 Million | 6.9% |
China Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 153.7 Million | 121212 | 6.4% |
Japan Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 50.5 Million | 121212 | 5.4% |
South Korea Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 43.91 Million | 121212 | 6% |
India Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 36.6 Million | 121212 | 8.8% |
Australia Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 19.03 Million | 121212 | 6.2% |
Singapore Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 7.32 Million | 121212 | 7.2% |
Taiwan Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 14.27 Million | 121212 | 6.7% |
South East Asia Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 24.15 Million | 121212 | 7.7% |
Rest of APAC Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 16.47 Million | 121212 | 6.7% |
South America Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 57.94 Million | $ 84.8 Million | 4.9% |
Brazil Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 24.8 Million | 121212 | 5.5% |
Argentina Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 9.73 Million | 121212 | 5.8% |
Colombia Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 5.16 Million | 121212 | 4.7% |
Peru Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 4.75 Million | 121212 | 5.1% |
Chile Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 4.17 Million | 121212 | 5.2% |
Rest of South America Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 9.33 Million | 121212 | 4% |
Middle East Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 60.99 Million | $ 93.2 Million | 5.4% |
Qatar Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 4.88 Million | 121212 | 4.9% |
Saudi Arabia Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 21.47 Million | 121212 | 5.7% |
Turkey Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 4.88 Million | 121212 | 6% |
UAE Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 12.56 Million | 121212 | 5.9% |
Egypt Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 3.66 Million | 121212 | 5.2% |
Rest of Middle East Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 13.54 Million | 121212 | 4.6% |
Africa Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 33.55 Million | $ 47.7 Million | 4.5% |
Nigeria Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 2.68 Million | 121212 | 4.7% |
South Africa Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 11.81 Million | 121212 | 5.4% |
Rest of Africa Adrenocorticotropic Hormone ACTH Market Sales Revenue | 121212 | $ 19.05 Million | 121212 | 3.7% |
Base Year | 2024 |
Historical Data Time Period | 2021-2024 |
Forecast Period | 2025-2033 |
Market Split by Source Outlook: |
|
Market Split by Application Outlook: |
|
Market Split by Distribution Channel Outlook: |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
|
Report scope is customizable as we have a huge database of Adrenocorticotropic Hormone ACTH industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Adrenocorticotropic Hormone ACTH Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Adrenocorticotropic hormone (ACTH) is a peptide hormone produced by the anterior pituitary gland that plays a crucial role in regulating the body’s response to stress. Its primary function is to stimulate the adrenal glands to produce and release cortisol, a steroid hormone essential for metabolism, immune function, and maintaining blood pressure. ACTH secretion is controlled by the hypothalamic-pituitary-adrenal (HPA) axis, which responds to various physiological and environmental stressors. It is also involved in regulating other adrenal hormones, such as androgens and aldosterone, which influence electrolyte balance and secondary sexual characteristics.
In June 2023, a collaborative research team led by Sumitomo Pharma announced a breakthrough in generating and purifying ACTH-secreting human pluripotent stem cell-derived pituitary cells. This innovative method enables the efficient production of high-purity pituitary hormone-producing cells, which, upon transplantation into hypopituitary mice, demonstrated long-term efficacy and responsive hormone secretion. This advancement holds promise for regenerative therapies targeting hypopituitarism. https://www.sumitomo-pharma.com/news/20230609.html
Endocrine disorders such as Cushing's disease, adrenal insufficiency, and congenital adrenal hyperplasia require ACTH-based therapies for diagnosis and treatment. With rising cases of adrenal gland dysfunctions, the demand for ACTH formulations has surged, particularly in regions where awareness and diagnosis rates are improving. According to the National Library of Medicine, retrospective and prospective analysis revealed a prevalence of adrenal crises 6.6-8.3 cases/100 patient-years, with mortality 0.5/100 patient-years, mainly due to gastrointestinal and other infectious diseases. In addition, lifestyle factors, stress, and genetic predisposition contribute to the growing incidence of endocrine conditions, further propelling market growth. Autoimmune disorders, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, have also been linked to an increased demand for ACTH treatments. ACTH plays a crucial role in stimulating cortisol production, which helps regulate immune responses and inflammation in such conditions. As the global burden of autoimmune diseases continues to rise, driven by genetic and environmental factors, the need for effective therapeutic options like ACTH-based treatments is expanding. Pharmaceutical companies are investing in research and development to enhance ACTH formulations, improve delivery methods, and address unmet medical needs that drive the growth in the market during the forecast period.
https://www.ncbi.nlm.nih.gov/books/NBK279083/Growing adoption of ACTH for diagnostic and therapeutic applications
In diagnostic settings, ACTH stimulation tests are widely used to assess adrenal gland function and diagnose conditions such as primary and secondary adrenal insufficiency, congenital adrenal hyperplasia, and Cushing’s syndrome. With the increasing awareness of adrenal disorders and advancements in diagnostic techniques, healthcare providers are relying more on ACTH-based tests to ensure accurate and early diagnosis. This trend is particularly strong in developed markets with well-established healthcare infrastructure, as well as in emerging economies where diagnostic capabilities are improving. Moreover, expanding clinical research into ACTH’s potential applications in new therapeutic areas is also contributing to market expansion. Ongoing studies are exploring its efficacy in neurological disorders, nephrotic syndrome, and even certain types of cancer, which open new opportunities for ACTH-based treatments.
The limited availability of adrenocorticotropic hormone (ACTH) formulations in certain regions poses a significant challenge to the growth of the ACTH market. Many developing and low-income countries face supply chain constraints, regulatory hurdles, and a lack of local manufacturing capabilities, making it difficult for healthcare providers to access ACTH-based therapies. As a result, patients suffering from adrenal insufficiency, infantile spasms, and autoimmune disorders struggle to obtain timely and effective treatment. The reliance on expensive imports further exacerbates the issue, leading to increased healthcare costs and limiting the widespread adoption of ACTH therapies. The high cost associated with ACTH formulations also limits their availability, particularly in healthcare systems with budget constraints. Many insurance providers and public health programs do not fully cover ACTH-based treatments, making them unaffordable for a large portion of the patient population. All these factors hamper the market growth.
The development of novel synthetic and recombinant adrenocorticotropic hormone (ACTH) analogs is creating significant opportunities for the expansion of the ACTH market. Traditional ACTH formulations, such as natural porcine or bovine-derived ACTH, often come with limitations, including variability in purity, supply chain constraints, and high production costs. In response, pharmaceutical companies are focusing on the research and development of synthetic and recombinant ACTH analogs that offer improved stability, potency, and consistency. These advancements are enabling the production of more effective and reliable ACTH-based therapies, driving their adoption across various therapeutic and diagnostic applications. Moreover, the expansion of biotechnology and advancements in peptide synthesis techniques are lowering production costs and improving the scalability of synthetic ACTH formulations. This has the potential to address supply shortages and enhance the global accessibility of ACTH therapies, especially in regions where traditional formulations are difficult to obtain.
Opportunity in Adrenocorticotropic Hormone Market
ACTH has long been used in the treatment of adrenal insufficiency and infantile spasms, but ongoing research is uncovering its potential in a wider range of rare endocrine, neurological, and autoimmune disorders. As regulatory agencies increasingly incentivize drug development for orphan diseases through accelerated approvals, tax benefits, and market exclusivity, pharmaceutical companies are investing in expanding ACTH’s therapeutic applications. This is driving market growth by positioning ACTH as a critical treatment option for previously underserved patient populations. Furthermore, the increasing awareness and diagnosis of rare diseases, coupled with advancements in genetic and biomarker-based diagnostics, are enabling earlier identification of patients which benefit from ACTH therapy.
We have various report editions of Adrenocorticotropic Hormone ACTH Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.
The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.
Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.
Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.
Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.
The Adrenocorticotropic Hormone Market is highly competitive, characterized by the presence of several global and regional players offering a wide range of products. Key companies in the market, such as Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Hikma Pharmaceuticals PLC, Avantor, Inc., Ferring B.V., Viatris, Inc., and Merck KGaA dominate through their extensive product portfolios, strong distribution networks, and focus on innovation.
In November 2021, ANI Pharmaceuticals received U.S. FDA approval for its Purified Cortrophin Gel, an ACTH formulation intended for treating chronic autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome. This approval reintroduces a significant treatment option for patients, especially those who are refractory or intolerant to corticosteroids. https://www.businesswire.com/news/home/20211101005292/en/ANI-Pharmaceuticals-Announces-FDA-Approval-of-Purified-Cortrophin%E2%84%A2-Gel-for-Multiple-Indications-Including-Multiple-Sclerosis-Rheumatoid-Arthritis-and-Nephrotic-Syndrome
Top Companies Market Share in Adrenocorticotropic Hormone ACTH Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
According to Cognitive Market Research, North America currently dominates the Adrenocorticotropic Hormone Market, and the region is expected to have significant growth during the projected period. Conditions such as adrenal insufficiency, Cushing’s syndrome, multiple sclerosis, and rheumatoid arthritis are on the rise in North America, leading to higher demand for ACTH-based therapies. In addition, the growing awareness and improved diagnosis of rare diseases, such as infantile spasms and nephrotic syndrome, have further fueled the adoption of ACTH treatments in the region.
Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). The rapid growth of the pharmaceutical and biotechnology sectors in countries such as China, India, Japan, and South Korea is a key factor contributing to market expansion. These nations are investing heavily in research and development, leading to advancements in synthetic and recombinant ACTH formulations. Collaborations between regional and global pharmaceutical companies are further accelerating innovation and the availability of ACTH therapies. In addition, regulatory agencies in Asia-Pacific are offering incentives for the development of orphan drugs, encouraging companies to introduce new ACTH-based treatments to address unmet medical needs.
The current report Scope analyzes Adrenocorticotropic Hormone ACTH Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
According to Cognitive Market Research, the global Adrenocorticotropic Hormone Market size was estimated at USD 1524.8 Million, out of which North America held the major market share of more than 37% of the global revenue with a market size of USD 564.18 million in 2025 and will grow at a compound annual growth rate (CAGR) of 2.7% from 2025 to 2033.
According to Cognitive Market Research, the US had a major share in the Adrenocorticotropic Hormone Market with a market size of USD 445.13 million in 2025 and is projected to grow at a CAGR of 2.5% during the forecast period.
The Canadian Adrenocorticotropic Hormone Market had a market share of USD 67.70 million in 2025 and is projected to grow at a CAGR of 3.5% during the forecast period. The increasing prevalence of autoimmune and endocrine disorders, such as multiple sclerosis and Cushing’s disease, is driving demand for ACTH-based therapies. In addition, government support for rare disease treatment and the availability of advanced healthcare infrastructure contribute to market growth. The expansion of clinical trials and research into novel ACTH formulations further strengthens market opportunities.
The Mexico Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD 51.34 million in 2025..
According to Cognitive Market Research, the global Adrenocorticotropic Hormone Market size was estimated at USD 1524.8 Million, out of which Europe held the market share of more than 29% of the global revenue with a market size of USD 442.19 million in 2025 and will grow at a compound annual growth rate (CAGR) of 3.3% from 2025 to 2033.
The United Kingdom Adrenocorticotropic Hormone Market had a market share of USD 74.29 million in 2025 and is projected to grow at a CAGR of 4.1% during the forecast period. The UK has a strong healthcare system with a focus on rare and orphan diseases, driving the demand for ACTH therapies. Increasing awareness among healthcare professionals and patients regarding endocrine disorders, along with government funding for research in peptide-based drugs, boosts market expansion. The presence of key pharmaceutical players and continuous advancements in peptide therapeutics further support the ACTH market.
The France Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 2.5% during the forecast period, with a market size of USD 40.68 million in 2025.
According to Cognitive Market Research, the Germanu Adrenocorticotropic Hormone Market size was valued at USD 87.55 million in 2025 and is projected to grow at a CAGR of 3.5% during the forecast period. Germany’s robust pharmaceutical industry and advanced healthcare infrastructure play a key role in the growth of the ACTH market. The country’s focus on innovative drug development, along with rising cases of autoimmune disorders, is propelling the demand for ACTH formulations. In addition, strong regulatory support for rare disease treatments and widespread insurance coverage for specialty drugs fuel market growth.
The Italy Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 38.03 million in 2025.
The Russia Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 2.3% during the forecast period, with a market size of USD 68.54 million in 2025
The Spain Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 2.4% during the forecast period with a market size of USD 36.26 million in 2025
The Sweden Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 3.4% during the forecast period, with a market size of USD 13.71 million in 2025.
The Denmark Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 3.1% during the forecast period, with a market size of USD 9.29 million in 2025
The Switzerland Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 2.9% during the forecast period, with a market size of USD 6.63 million in 2025.
The Luxembourg Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 3.6% during the forecast period, with a market size of USD 5.31 million in 2025.
The Rest of Europe's Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 2.0% during the forecast period, with a market size of USD 61.91 million in 2025.
According to Cognitive Market Research, the global Adrenocorticotropic Hormone Market size was estimated at USD 1524.8 Million, out of which APAC held the market share of around 24% of the global revenue with a market size of USD 365.95 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.9% from 2025 to 2033.
According to Cognitive Market Research, the China Adrenocorticotropic Hormone Market size was valued at USD 153.70 million in 2025 and is projected to grow at a CAGR of 6.4% during the forecast period. The rapidly growing pharmaceutical sector in China, coupled with increasing healthcare expenditure, is driving demand for ACTH treatments. Rising awareness and diagnosis rates of pituitary and adrenal disorders, along with the expansion of clinical trials for ACTH analogs, create opportunities for market growth. In addition, government initiatives to improve access to rare disease medications are supporting the adoption of ACTH therapies.
The Japan Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 5.4% during the forecast period, with a market size of USD 50.50 million in 2025
The South Korea Adrenocorticotropic Hormone Market had a market share of USD 43.91 million in 2025 and is projected to grow at a CAGR of 6.0% during the forecast period. South Korea’s investment in biopharmaceutical research and development, along with increasing cases of autoimmune diseases, is driving the demand for ACTH formulations. The country’s advanced healthcare infrastructure and supportive reimbursement policies for rare disease treatments contribute to market expansion. In addition, ongoing clinical studies on peptide-based therapeutics enhance the market’s growth potential.
The Indian Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 8.8% during the forecast period, with a market size of USD 36.60 million in 2025.
The Australian Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 6.2% during the forecast period, with a market size of USD 19.03 million in 2025.
The Singapore Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 7.32 million in 2025.
The Taiwan Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 14.27 million in 2025.
The South East Asia Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 24.15 million in 2025.
The Rest of APAC Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 16.47 million in 2025.
According to Cognitive Market Research, the global Adrenocorticotropic Hormone Market size was estimated at USD 1524.8 Million, out of which South America held the market share of around 4% of the global revenue with a market size of USD 84.8 million in 2025 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2025 to 2033.
According to Cognitive Market Research, the Brazil Adrenocorticotropic Hormone Market size was valued at USD 24.80 million in 2025 and is projected to grow at a CAGR of 5.5% during the forecast period. The growing burden of endocrine disorders and the increasing availability of specialty drugs in Brazil are key factors driving the ACTH market. Government initiatives to improve access to rare disease treatments, coupled with expanding healthcare infrastructure, are fueling market growth. In addition, the presence of international pharmaceutical companies investing in Latin America’s specialty drug sector contributes to increased adoption of ACTH therapies.
Argentina's Adrenocorticotropic Hormone Market had a market share of USD 9.73 million in 2025 and is projected to grow at a CAGR of 5.8% during the forecast period. The increasing prevalence of adrenal insufficiency and autoimmune disorders is driving the demand for ACTH in Argentina. Government efforts to improve access to rare disease medications through healthcare programs, along with the growing pharmaceutical sector, are supporting market growth. In addition, the presence of research institutions conducting clinical studies on hormonal therapies enhances the adoption of ACTH treatments.
Colombia Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 5.16 million in 2025
Peru Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 5.1% during the forecast period, with a market size of USD 4.75 million in 2025.
Chile Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 4.17 million in 2025
The Rest of South America's Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 9.33 million in 2025.
According to Cognitive Market Research, the global Adrenocorticotropic Hormone Market size was estimated at USD 1524.8 Million, out of which the Middle East held the major market share of around 4% of the global revenue with a market size of USD 60.99 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2033.
The Qatar Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 4.9% during the forecast period, with a market size of USD 4.88 million in 2025. Qatar’s high per capita healthcare expenditure and focus on specialized treatments for rare diseases contribute to the growth of the ACTH market. The country’s advanced medical facilities and increasing diagnosis rates of pituitary disorders drive demand for ACTH formulations. In addition, government initiatives to strengthen the pharmaceutical sector and attract international drug manufacturers support market expansion.
The Saudi Arabia Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 21.47 million in 2025.
The Turkey Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 4.88 million in 2025. The growing awareness of endocrine disorders and improving healthcare infrastructure in Turkey are driving the demand for ACTH therapies. The country’s expanding pharmaceutical sector and increasing adoption of advanced peptide therapeutics are boosting market growth. In addition, government support for rare disease treatments through reimbursement programs is enhancing accessibility to ACTH formulations.
The UAE Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 5.9% during the forecast period, with a market size of USD 12.56 million in 2025.
The Egypt Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 3.66 million in 2025.
The Rest of the Middle East Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD 13.54 million in 2025
According to Cognitive Market Research, the global Adrenocorticotropic Hormone Market size was estimated at USD 1524.8 Million, out of which the Africa held the major market share of around 2.2% of the global revenue with a market size of USD 33.55 million in 2025 and will grow at a compound annual growth rate (CAGR) of 4.5% from 2025 to 2033..
The Nigeria Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 2.68 million in 2025. The rising prevalence of adrenal insufficiency and limited access to alternative treatment options are driving the ACTH market in Nigeria. Increasing investments in healthcare infrastructure and growing awareness of rare endocrine disorders contribute to market expansion. In addition, partnerships between local healthcare providers and international pharmaceutical firms are improving access to ACTH therapies in the country.
The South Africa Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 5.4% during the forecast period, with a market size of USD 11.81 million in 2025.
The Rest of Africa Adrenocorticotropic Hormone Market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 19.05 million in 2025.
Global Adrenocorticotropic Hormone ACTH Market Report 2025 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Adrenocorticotropic Hormone ACTH Industry growth. Adrenocorticotropic Hormone ACTH market has been segmented with the help of its Source Outlook:, Application Outlook: Distribution Channel Outlook:, and others. Adrenocorticotropic Hormone ACTH market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
How are Segments Performing in the Global Adrenocorticotropic Hormone Market?
According to Cognitive Market Research, synthetic segment is likely to dominate the oakmoss extract market. Synthetic ACTH offers higher purity, consistency, and safety. Innovations in recombinant DNA technology and peptide engineering have enabled the development of stable and effective synthetic ACTH analogs with improved pharmacokinetics. These advancements have increased the adoption of synthetic ACTH in both diagnostic and therapeutic applications that makes it a preferred choice for healthcare providers. Moreover, regulatory and market trends are also favoring the growth of synthetic ACTH. Governments and regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are encouraging the development of synthetic hormone therapies due to their safety and consistency.
The expansion of synthetic markets provides opportunities for adrenocorticotropic hormone. Advancements in biotechnology and drug delivery systems are creating new growth opportunities for market. The development of long-acting synthetic ACTH formulations with enhanced bioavailability and reduced dosing frequency can improve patient compliance and treatment outcomes. In addition, ongoing research into recombinant ACTH analogs is expected to introduce innovative therapies with better safety profiles. With increasing investment in synthetic peptide drugs, pharmaceutical companies have the potential to expand their market reach by introducing novel ACTH formulations in regions where access to traditional ACTH treatments has been limited.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Adrenocorticotropic Hormone ACTH Industry. Request a Free Sample PDF!
According to Cognitive Market Research, the neurology segment holds the largest share of the market. Infantile spasms (West syndrome), a severe form of epilepsy in infants, is one of the primary neurological conditions where ACTH remains the standard treatment. The rising awareness of infantile spasms among healthcare providers, along with improved early diagnosis, has significantly boosted the demand for ACTH in neurology. In addition, multiple sclerosis (MS), an autoimmune disease affecting the central nervous system, has seen a surge in cases globally. Moreover, ACTH is used as an alternative treatment for MS relapses, especially in patients who do not respond well to corticosteroids that also drives the market growth.
In the Adrenocorticotropic Hormone Market, the nephrotic syndrome segment has been expanding at a rapid pace. The adrenocorticotropic hormone (ACTH) market in nephrotic syndrome presents significant growth opportunities due to its increasing adoption as a treatment option, especially for patients with steroid-resistant nephrotic syndrome (SRNS). Many nephrotic syndrome cases do not respond well to conventional corticosteroid therapy, leading physicians to explore alternative treatments like ACTH. Synthetic ACTH formulations have shown promising results in reducing proteinuria and inflammation that makes them a viable option for managing this kidney disorder.
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
According to Cognitive Market Research, hospital pharmacies segment holds the largest market share. The adrenocorticotropic hormone (ACTH) market in hospital pharmacies is driven by the increasing hospitalization rates of patients with endocrine, neurological, and autoimmune disorders that require ACTH-based treatments. Conditions such as adrenal insufficiency, infantile spasms, multiple sclerosis, nephrotic syndrome, and rheumatoid arthritis often require immediate and controlled administration of ACTH, making hospital pharmacies the primary distribution channel. The availability of ACTH in hospital settings ensures that patients receive timely treatment under medical supervision, especially in critical care and emergency situations, driving demand in this segment.
In the Adrenocorticotropic Hormone Market, the rapidly growing distribution channel is the retail pharmacies category. Favorable insurance and reimbursement policies are creating new growth avenues for ACTH in retail pharmacies. Governments and private healthcare insurers in regions such as North America, Europe, and Asia-Pacific are increasingly covering ACTH treatments under outpatient care benefits. This makes it easier for patients to purchase ACTH medications from retail pharmacies without bearing high out-of-pocket costs. As awareness of ACTH’s role in managing endocrine, neurological, and autoimmune disorders increases, retail pharmacies are poised to become a major distribution channel, driving market growth and enhancing patient access to life-saving hormone therapies.
Senior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Conclusion
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Disclaimer:
Source Outlook: | Natural, Synthetic |
Application Outlook: | Rheumatology, Neurology, Nephrotic Syndrome, Ophthalmology, Others |
Distribution Channel Outlook: | Hospital Pharmacies, Retail Pharmacies, Online Sales |
List of Competitors | Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Hikma Pharmaceuticals PLC, Avantor, Inc., Ferring B.V., Viatris, Inc., Merck KGaA |
This chapter will help you gain GLOBAL Market Analysis of Adrenocorticotropic Hormone ACTH. Further deep in this chapter, you will be able to review Global Adrenocorticotropic Hormone ACTH Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
This chapter will help you gain North America Market Analysis of Adrenocorticotropic Hormone ACTH. Further deep in this chapter, you will be able to review North America Adrenocorticotropic Hormone ACTH Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
This chapter will help you gain Europe Market Analysis of Adrenocorticotropic Hormone ACTH. Further deep in this chapter, you will be able to review Europe Adrenocorticotropic Hormone ACTH Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
This chapter will help you gain Asia Pacific Market Analysis of Adrenocorticotropic Hormone ACTH. Further deep in this chapter, you will be able to review Asia Pacific Adrenocorticotropic Hormone ACTH Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
This chapter will help you gain South America Market Analysis of Adrenocorticotropic Hormone ACTH. Further deep in this chapter, you will be able to review South America Adrenocorticotropic Hormone ACTH Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
This chapter will help you gain Middle East Market Analysis of Adrenocorticotropic Hormone ACTH. Further deep in this chapter, you will be able to review Middle East Adrenocorticotropic Hormone ACTH Market Split by various segments and Country Split.
Chapter 6 Middle East Market Analysis
This chapter will help you gain Middle East Market Analysis of Adrenocorticotropic Hormone ACTH. Further deep in this chapter, you will be able to review Middle East Adrenocorticotropic Hormone ACTH Market Split by various segments and Country Split.
Chapter 7 Africa Market Analysis
This chapter provides an in-depth analysis of the market share among key competitors of Adrenocorticotropic Hormone ACTH. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Source Outlook: Analysis 2019 -2031, will provide market size split by Source Outlook:. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Source Outlook: Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Outlook: Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Distribution Channel Outlook: Analysis 2021 - 2033
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Adrenocorticotropic Hormone ACTH market
Chapter 13 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Chapter 14 Research Methodology and Sources
Why Natural have a significant impact on Adrenocorticotropic Hormone ACTH market? |
What are the key factors affecting the Natural and Synthetic of Adrenocorticotropic Hormone ACTH Market? |
What is the CAGR/Growth Rate of Rheumatology during the forecast period? |
By type, which segment accounted for largest share of the global Adrenocorticotropic Hormone ACTH Market? |
Which region is expected to dominate the global Adrenocorticotropic Hormone ACTH Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|